• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

    2/9/23 11:07:47 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care
    Get the next $ATRC alert in real time by email
    SC 13G/A 1 tv0340-atricureinc.htm SCHEDULE 13G/A atricureinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 3)*

    Name of issuer:  AtriCure Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  04963C209

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  04963C209

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    61,158

    7.  SOLE DISPOSITIVE POWER

    4,283,657

    8.  SHARED DISPOSITIVE POWER

    106,158

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,389,815

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.44%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    AtriCure Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    7555 Innovation Way
    Mason, OH 45040

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    04963C209

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ATRC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATRC

    DatePrice TargetRatingAnalyst
    12/17/2024$40.00Overweight
    Analyst
    4/23/2024$32.00Perform → Outperform
    Oppenheimer
    10/23/2023$60.00Mkt Outperform
    JMP Securities
    9/29/2023$56.00Buy
    UBS
    2/16/2022$120.00 → $88.00Buy
    Canaccord Genuity
    2/16/2022$92.00 → $79.00Buy
    Needham
    11/4/2021$90.00 → $92.00Buy
    Needham
    11/4/2021$100.00 → $110.00Outperform
    SVB Leerink
    More analyst ratings

    $ATRC
    Financials

    Live finance-specific insights

    See more
    • AtriCure Reports First Quarter 2025 Financial Results

      Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. "Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business," said Michael Carrel, President and Chief Executiv

      4/29/25 4:01:00 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure to Announce First Quarter 2025 Financial Results

      AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, April 29, 2025, to discuss its first quarter 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://

      4/8/25 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

      Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year Launched cryoSPHERE®+, cryoSPHERE MAX™ and AtriClip® FLEX-Mini™ devices in the United States, and EnCompass® clamp in Europe AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. "2024 was another outstanding year at AtriCure, marked by continued progress on driving growth, improving profi

      2/12/25 4:01:00 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by AtriCure Inc.

      SC 13G - AtriCure, Inc. (0001323885) (Subject)

      11/14/24 8:00:04 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

      SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

      2/14/24 2:56:38 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

      SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

      2/13/24 4:58:56 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Leadership Updates

    Live Leadership Updates

    See more
    • AtriCure Appoints Shlomi Nachman to the Board of Directors

      AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck

      1/4/24 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer

      AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo

      6/1/22 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst resumed coverage on AtriCure with a new price target

      Analyst resumed coverage of AtriCure with a rating of Overweight and set a new price target of $40.00

      12/17/24 7:29:01 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded AtriCure from Perform to Outperform and set a new price target of $32.00

      4/23/24 6:23:54 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • JMP Securities initiated coverage on AtriCure with a new price target

      JMP Securities initiated coverage of AtriCure with a rating of Mkt Outperform and set a new price target of $60.00

      10/23/23 7:18:47 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Doraiswamy Vinayak sold $83,600 worth of shares (2,500 units at $33.44), decreasing direct ownership by 3% to 73,550 units (SEC Form 4)

      4 - AtriCure, Inc. (0001323885) (Issuer)

      5/30/25 4:21:03 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • Director Yuen Maggie was granted 5,401 shares, increasing direct ownership by 60% to 14,371 units (SEC Form 4)

      4 - AtriCure, Inc. (0001323885) (Issuer)

      5/21/25 4:57:46 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • Director White Robert S. was granted 5,401 shares, increasing direct ownership by 5% to 112,174 units (SEC Form 4)

      4 - AtriCure, Inc. (0001323885) (Issuer)

      5/21/25 4:42:54 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care

    $ATRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ATRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ATRC
    SEC Filings

    See more
    • Privitera Salvatore bought $111,250 worth of shares (5,000 units at $22.25), increasing direct ownership by 5% to 103,290 units (SEC Form 4)

      4 - AtriCure, Inc. (0001323885) (Issuer)

      5/31/24 4:12:34 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib af

      5/23/25 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure Reports First Quarter 2025 Financial Results

      Worldwide revenue of $123.6 million – an increase of 13.6% year over year (14.1% constant currency) Net loss of $6.7 million – an improvement of $6.5 million year over year Adjusted EBITDA of $8.8 million – an increase of $6.0 million year over year AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. "Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business," said Michael Carrel, President and Chief Executiv

      4/29/25 4:01:00 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure Announces First Use of the AtriClip PRO-Mini® Device

      AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced the first use of the newest AtriClip ® device for minimally invasive concomitant procedures, the AtriClip PRO-Mini® LAA Exclusion System. The AtriClip PRO-Mini device received FDA 510K clearance earlier this year and is a testament to AtriCure's commitment to innovating the lowest profile and most effective surgical LAA devices on the market. Building upon the proven technology of AtriCure's AtriClip platform as the most widely implanted surgical LAA device globally, the AtriClip PRO-Mini

      4/10/25 8:00:00 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by AtriCure Inc.

      SD - AtriCure, Inc. (0001323885) (Filer)

      5/29/25 8:50:54 AM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • AtriCure Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - AtriCure, Inc. (0001323885) (Filer)

      5/20/25 4:29:26 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by AtriCure Inc.

      SCHEDULE 13G - AtriCure, Inc. (0001323885) (Subject)

      5/14/25 4:02:21 PM ET
      $ATRC
      Medical/Dental Instruments
      Health Care